Cardiovascular disease is one of the major causes of death worldwide and assessing the risk is an important aspect in clinical decision making and setting a therapeutic strategy. Biological biomarkers generally refer to measurable indicators of some biological state or condition. The use of easily applicable serological biomarkers would be a great benefit for diagnosis, prognosis and risk stratification of cardiovascular diseases. Microparticles (MPs) derived from vascular endothelium or circulating blood cells circulate in the peripheral blood and are present in low concentrations in normal plasma. In our working group we investigate the course of circulating microparticles, exosomes, miRNA or molecular biomarkers and their correlation with echocardiographic parameters to predict left ventricular hypertrophy, prosthesis-patient-mismatches and adverse outcomes after cardiac surgeries.
· Exosome characterization with nanoparticle tracking analysis
· Sorting of MPs for their cellular origin with fluorescence activated cell sorting (FACS)
· miRNA analysis with qRT-PCR
· Serum and plasma analysis of molecular biomarkers, such as OPN, ST2 or CD137
· Univ.-Prof. Dr. P. Akhyari
· Vera Schmidt, M.Sc.
· cand. med. Shining Sophie Liu
· cand. med. Lauren Giovanna Lageveen
· cand. med. Letizia Cardone
· cand. med. Yeo Min Lee
· cand. med. Kathrin Lanhenke
· cand. med. Annalena Louisa Büttner